Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChan Y. CheahJJJieying JiangMAMohammad Atiya

Discussion

Loading...

Member takes

Overview

Analysis reveals sustained responses in large B-cell lymphoma patients amid treatment pauses or discontinuation, indicating favorable outcomes.

Key Points

  • This analysis evaluates the durability of response in patients with relapsed/refractory large B-cell lymphoma who paused or discontinued epcoritamab while in complete response.
  • Patients with relapsed/refractory CD20+ large B-cell lymphoma were analyzed for treatment pauses or discontinuation.
  • Epcoritamab was administered subcutaneously at approved dosing schedules in cycles until progression or toxicity.
  • Primary endpoint assessed was overall response rate per Lugano criteria.
  • Patients who paused treatment had a median follow-up time of 37.0 months and maintained their complete response.
  • Median progression-free survival was reported as not reached; reasons for pauses included adverse events.
  • For patients who discontinued treatment, the median follow-up time was 37.1 months with sustained remissions reported.

Cite This Study

Cheah et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d519https://doi.org/10.1182/blood-2025-5511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  2. 2Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial2026 · 4 citations
  3. 3Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).2024 · 9 citations
  4. 4Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial2025 · 4 citations
  5. 5Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 2 citations